SupportLoginSign Up
Featured FeedJournalsCollectionsKeywordsSaved Papers
Add like
Add dislike
Add to saved papers

On cost-effectiveness analysis, quality-adjusted life years, and cost-effectiveness threshold values of gemcitabine plus nab-paclitaxel versus gemcitabine alone in metastatic pancreatic cancer in the French setting.

Carlo Lazzaro
Therapeutic Advances in Medical Oncology 2024
No abstract text is available yet for this article.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.
Show additional links to paperHide additional links to paper
PubMed

Add to Saved Papers

Get 1-tap access

Related Resources

Trending Papers

How to Approach Patients with Acute Chest Pain.Kenji Inoue, Tohru MinaminoReviews in Cardiovascular Medicine 2024 August
Novel Insights into Diabetic Kidney Disease.Ewelina Młynarska et al.International Journal of Molecular Sciences 2024 September 23
Central venous catheter insertion site and infection prevention in 2024.Harm-Jan de Grooth, Stefan Hagel, Olivier MimozIntensive Care Medicine 2024 September 30

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Do Not Sell My Personal InformationManage Cookie Preferences

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app